China Pharma Holdings (CPHI) Cash from Investing Activities (2010 - 2025)
China Pharma Holdings' (CPHI) quarterly Cash from Investing Activities came in at -$5767.0 in Q4 2025, up 97.89% on a YoY basis from -$2914.3 in Q4 2024, and up 92.12% quarter-over-quarter from -$73225.0 in Q3 2025.
Powered by 
Analysis
China Pharma Holdings (CPHI) Cash from Investing Activities (2010 - 2025) Analysis & Trends
China Pharma Holdings (CPHI) has reported Cash from Investing Activities for 16 consecutive years, with -$5767.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities rose 97.89% year-over-year to -$5767.0; the trailing twelve-month figure through Dec 2025 stood at -$137251.0 (up 59.1% YoY), and the FY2025 full-year result was -$137251.0, up 52.95% from the prior year.
- Cash from Investing Activities improved to -$5767.0 in Q4 2025 per CPHI's latest filing, from -$73225.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $55964.0 in Q1 2023 and bottomed at -$415977.0 in Q3 2021.
- Historically, Cash from Investing Activities has averaged -$77337.3 across 5 years, with a median of -$6411.5 in 2021.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities jumped 4123.29% in 2023, then sank 5927.21% in 2024.
- Over 5 years, Cash from Investing Activities stood at -$7056.0 in 2021, then jumped by 486.45% to $27268.0 in 2022, then plunged by 116.6% to -$4527.0 in 2023, then tumbled by 5927.21% to -$272852.0 in 2024, then surged by 97.89% to -$5767.0 in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$5767.0, -$73225.0, and $65.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | -1.11 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -1.20 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -5.60 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -3.11 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.11 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -424.26 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | -1.66 Bn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | -51.79 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 87.50 Mn |
| 10 | China Pharma Holdings | 31.39 Mn | 31.08 Mn | 83,566.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -5,767.00 |
| Sep 30, 2025 | -73,225.00 |
| Jun 30, 2025 | 65.00 |
| Mar 31, 2025 | -58,324.00 |
| Dec 31, 2024 | -272,852.00 |
| Sep 30, 2024 | 9,220.00 |
| Dec 31, 2023 | -4,527.00 |
| Sep 30, 2023 | -67,455.00 |
| Jun 30, 2023 | 4,501.00 |
| Mar 31, 2023 | 55,964.00 |
| Dec 31, 2022 | 27,268.00 |
| Sep 30, 2022 | -252,550.00 |
| Jun 30, 2022 | -175,291.00 |
| Mar 31, 2022 | -1,391.00 |
| Dec 31, 2021 | -7,056.00 |
| Sep 30, 2021 | -415,977.00 |
| Dec 31, 2020 | 232,571.00 |
| Sep 30, 2020 | -259,429.00 |
| Jun 30, 2020 | -492,654.00 |
| Mar 31, 2020 | -347,795.00 |